Trump Administration Tightens H-1B Visa Vetting With New Focus on Free Speech and Censorship 
Taiwan Opposition Criticizes Plan to Block Chinese App Rednote Over Security Concerns 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Trump Administration Halts Immigration, Green Card, and Citizenship Processing for 19 Countries 
Drones Spotted Near Zelenskiy’s Flight Path in Ireland Trigger Security Alert 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
U.S. Expected to Expand Travel Ban to More Than 30 Countries 
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Trump Calls for Permanent Pause on Migration After National Guard Shooting Near White House 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
